abstract |
Disclosed is a pharmaceutical agent that inhibits heat shock protein 90 (Hsp90), has the ability to cross the blood-brain barrier, or is otherwise delivered to the brain as a clinical drug for the treatment of neurodegenerative diseases. A pharmaceutical effective for the treatment of a neurodegenerative disease comprising a compound of a small molecule purine skeleton represented by the following formula. A pharmaceutical product having the flexibility and substituents necessary for the compound as a whole to be received within the N-terminal pocket of Hsp90. However, pharmaceuticals that are not PO-BS112, PU-BS-18, PU-BS-16, PU-BS111, PU-HZ150, or the like. [Selection figure] None |